A wonderful moment meeting Drs. Ugrakli & Artac from @NEUniversitesi at #ESMO26. Dr. Ugrakli noted that she modelled her study of nivolumab +/- BL-04 (a Bifidobacterium animalis strain) after seeing @NazliDizman discuss her work related to #CBM588. Take a close look - interesting early OS signal. There are so many hidden gems in the poster sessions; do try to attend! @OncoAlert @DrYukselUrun @yekeduz_emre @ziremozay
78 views · 6 likes · 1 repost · 0 replies
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgPost-surgical molecular residual disease and pathological complete response after perioperative nivolumab in resectable stage III NSCLC: Exploratory analysis from NADIM II
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.orgSource: Sumanta K. Pal, MD, FASCO · x.com